Bharat Biotech Acquires Chiron Behring Vaccines

Hyderabad, India, February 15th 2019: Bharat Biotech announces the forthcoming acquisition of Chiron Behring Vaccines Pvt Ltd, located in Ankleshwar, Gujarat from GlaxoSmithKline Asia. Bharat Biotech will acquire 100% equity stake in Chiron Behring Vaccines in an all cash transaction, subject to a number of closing conditions which Bharat Biotech and GSK intend to complete in the coming weeks.

Chiron Behring Vaccines was formed as a result of the purchase of the vaccines business of Hoechst AG by Chiron Corporation USA. It is one of the largest manufacturers of high quality rabies vaccines in the world. Chiron Behring Vaccines is a WHO Pre-qualified manufacturer of rabies vaccines, eligible for supplies to UN agencies and has product registrations in more than 20 countries. The rabies vaccine manufactured at Ankleshwar is a result of decades of research & product development.

Bharat Biotech has a wide portfolio of vaccines, with market access to more than 70 countries. The addition of this rabies vaccine will establish Bharat Biotech as a global leader in rabies vaccines manufacturing. Bharat Biotech plans to enhance upon the manufacturing capabilities at Chiron Behring Vaccines and expand market access through product registrations in additional high demand countries.

Announcing the deal, Dr. Krishna Ella, Chairman and Managing Director of Bharat Biotech, said:

“This acquisition is strategic in helping us enhance our opportunities to achieve greater scale in tackling public health problems. Bharat Biotech will strengthen its product portfolio and substantially increase product availability in response to the growing demand for this vaccine. With the significant disease burden of rabies in India and other countries, I appreciate GSK’s vision in this transition to Bharat Biotech, to continue to meet the needs of the patients.”

According to WHO report, rabies is a vaccine-preventable disease claiming the lives of over 55,000 people each year, mostly in Asia & Africa. India accounts for 36% of the world’s rabies deaths.

About Bharat Biotech

Bharat Biotech is a clone to clinic biotechnology company focused on innovative product development, global manufacturing capabilities and internationally recognised quality management systems.

Bharat Biotech has established an excellent track record of innovation with more than 100 global patents, a wide product portfolio of more than 15 products, registrations in more than 70 countries and WHO Pre-qualifications.

Our commitment to global social innovation programs and public private partnerships resulted in the introduction of path breaking WHO pre-qualified vaccines BIOPOLIO® “ROTAVAC®” and Typbar TCV™ combatting polio, rotavirus, typhoid infections respectively.

We have increased access for governments and communities to safe, effective and affordable vaccines to avert life threatening diseases including Hepatitis B, Rabies, Japanese Encephalitis, H1N1, Polio, as well as
bio-therapeutics using recombinant epidermal growth factors in the treatment of diabetic foot ulcers and burns.

For more information about our continuing innovations, product portfolio and research pipeline, visit www.bharatbiotech.com and connect with us on Facebook.

BBIL was advised in this transaction by Mr. Ranga Iyer and LVV Iyer & Associates.

About GSK:

GSK – a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer.

GSK is one of the world’s leading vaccine companies, with a broad portfolio and innovative pipeline of vaccines to help protect people throughout life. We have more than 17,000 people working worldwide to deliver over two million vaccine doses per day to people in more than 160 countries.
For further information, please visit www.gsk.com 

GSK was advised in this transaction by Nova Dhruva Capital Pvt. Ltd. and Talwar Thakore & Associates.

For further information:

Bharat Biotech: Sheela Panicker | +91 984 980 9594 | enright@enrightpr.com

FORWARD LOOKING STATEMENTS

This document may contain forward-looking statements. These forward-looking statements involve significant risks and uncertainties. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including all statements regarding information regarding the intent, belief or current expectation of Bharat Biotech/ CBVPL (the “Company”) and members of its senior management team. Forward-looking statements include, without limitation, statements regarding prospective performance and opportunities and the outlook for the Company’s businesses, performance and opportunities and regulatory approvals, the anticipated timing of filings and approvals relating to the transaction; the expected timing of the completion of the transaction; the ability to complete the transaction considering the various closing conditions; and any assumptions underlying any of the foregoing.